Liquidia Corporation specializes in the research, development, and commercialization of treatments for rare cardiopulmonary conditions. The company's lead product candidate is YUTREPIA, an inhaled dry powder formulation of treprostinil designed to treat pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung disease (PH-ILD). Liquidia is also developing L606, an investigational liposomal formulation of treprostinil, and markets a generic Treprostinil Injection in partnership with Sandoz. A key competitive advantage is its proprietary PRINT (Particle Replication In Non-wetting Templates) technology, which enables the precise engineering of drug particles to optimize delivery and efficacy. The company operates primarily in the United States and is headquartered in Morrisville, North Carolina.
